8th Jan 2016 07:00
8 January 2016
Clinigen Group plc
Notification of half year trading update
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, will announce a half year trading update for the six months ended 31 December 2015 on Tuesday 19 January 2016.
An analyst call will be held at 9:30am on Tuesday, 19 January 2016.
Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email [email protected] for conference call details.
-Ends-
Contact Details
Clinigen Group plc |
Tel: +44 (0) 1283 495010 |
Peter George, Group Chief Executive Officer Shaun Chilton, Group Deputy CEO Martin Abell, Group Chief Financial Officer |
|
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade/Freddie Barnfield (Nominated Adviser) James Black/Tom Ballard (Corporate Broking) |
|
Peel Hunt LLP | Tel: +44 (0) 20 7418 8900 |
James Steel/Jock Maxwell Macdonald |
|
Instinctif Partners | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell/Jayne Crook/Emma Barlow | Email: [email protected] |
About Clinigen Group
Clinigen Group is a global pharmaceutical and services company with a unique combination of businesses dedicated to delivering the right drug to the right patient at the right time.
The Group consists of four synergistic businesses that provide medicines to patients with unmet medical need; through Clinigen Clinical Trial Services we manage the supply of commercial medicines for clinical trials, through Idis Managed Access we run early access programs for our own and other companies' portfolios, our Idis Global Access team works directly with healthcare providers to enable ethical compliant access to unlicensed medicines, and through Clinigen Specialty Pharmaceuticals, we market our own portfolio of niche commercial products.
Clinigen is the global leader in ethically sourcing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet need, and in the supply of comparator and adjuvant therapies for clinical trials. In October 2015, Clinigen acquired Link Healthcare, further strengthening our international distribution network in the AAA region - Asia, Africa and Australasia.
For more information, please visit www.clinigengroup.com
Related Shares:
CLIN.L